Skip to main content
. Author manuscript; available in PMC: 2016 Nov 28.
Published in final edited form as: Oncogene. 2016 May 2;35(47):6087–6095. doi: 10.1038/onc.2016.146

Figure 2. SALL4B transgenic mice had HR deficiency but not NHEJ in DNA damage repair, and SALL4B transgenic mice had chromosomal instability after MMC treatment.

Figure 2

(a) HR and NHEJ reporter assay was performed on pre-leukemic SALL4B Tg mice and WT control. (b) & (c) SALL4B transgenic mice bone marrow cells were more sensitive to DNA damage drug MMC treatment by producing more chromosomal aberrations (radial changes) (ii) than WT control (i).